We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study) (RENSYMPIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01785732
Recruitment Status : Unknown
Verified February 2013 by The Hospital District of Satakunta.
Recruitment status was:  Recruiting
First Posted : February 7, 2013
Last Update Posted : February 11, 2013
Information provided by (Responsible Party):
The Hospital District of Satakunta

February 5, 2013
February 7, 2013
February 11, 2013
January 2013
January 2014   (Final data collection date for primary outcome measure)
Office blood pressure [ Time Frame: 2 years ]
Same as current
Complete list of historical versions of study NCT01785732 on ClinicalTrials.gov Archive Site
  • Ambulatory blood pressure [ Time Frame: 2 years ]
  • Insulin resistance [ Time Frame: 2 years ]
  • Endothelial function [ Time Frame: 2 years ]
Same as current
Not Provided
Not Provided
Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study)
Not Provided

Hypertension is a major risk factor for stroke and cardiovascular mortality. Catheter- based renal denervation causes substantial and sustained blood- pressure reduction in patients with resistant hypertension.

The purpose of RENSYMPIS is to study the effects of renal denervation on:

  1. Cardiovascular function
  2. Metabolic factors
  3. Inflammatory and endocrine factors
  4. Coagulation
  5. Sleep
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Resistant Hypertension
Procedure: Renal Denervation
Sympathetic renal denervation via renal arteries
  • Active Comparator: Renal denervation
    Patients are randomized to renal denervation
    Intervention: Procedure: Renal Denervation
  • No Intervention: Optimization of medical therapy
    Antihypertensive treatment is optimized
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
January 2016
January 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Resistant Hypertension (systolic blood pressure >160mmHg and 3 or more antihypertensive agents in use)
  • Age 30- 69 years
  • Written informed consent

Exclusion Criteria:

  • Secondary hypertension
  • Pseudohypertension
  • Pregnancy
  • Renal insufficiency (GFR <45ml/min)
  • Clinically significant stenotic valvular disease
  • Oral anticoagulation
  • CCS III-IV symptoms or CABG/PCI in previous 6 months
  • Prior stroke
  • Contrast agent allergy
  • inappropriate renal artery anatomy (< 4mm diameter, < 20mm length)
Sexes Eligible for Study: All
30 Years to 69 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
The Hospital District of Satakunta
The Hospital District of Satakunta
Not Provided
Not Provided
The Hospital District of Satakunta
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP